Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Artgen Biotech reported for 9 months of 2023

1/18/24 ABIO

Cosmos Hotel aims to capture 15-20% of the hotel market by 2026

1/18/24 AFKS

Whoosh intends to increase the density of coverage

1/18/24 WUSH

VTB to launch VTB Pay payment application in 2024

1/18/24 VTBR

UTair aircraft passenger traffic in 2023 increased by 9.3%

1/18/24 UTAR

M.Video-Eldorado registers trademark for additional services

1/18/24 MVID

Nornickel and Rosatom additional capitalization of Polar Lithium

1/17/24 GMKN

Rostelecom's revenue in 2023 exceeds ₽700 billion

1/17/24 RTKM

Aeroflot passenger turnover up 25.4% in 2023

1/17/24 AFLT

Novatek in 2023 sold 2.7% more gas

1/17/24 NVTK